Pharmacology of Restless Legs Syndrome (RLS)

1. Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transportSergi Ferré, César Quiroz, William Rea, Xavier Guitart and Diego García-Borreguero2. D3 receptor agonist efficacy in restless legs syndromeFrancesca Casoni, Andrea Galbiati and Luigi Ferini-Strambi3. The heterotetrameric structure of the adenosine A1-dopamine D1 receptor complex: Pharmacological implication for restless legs syndromeAntoni Cortés, Verònica Casadó-Anguera, Estefanía Moreno and Vicent Casadó4. D3 and D1 receptors: The Yin and Yang in the treatment of restless legs syndrome with dopaminergicsStefan Clemens and Imad Ghorayeb5. The neurophysiology of hyperarousal in restless legs syndrome: Hints for a role of glutamate/GABAGiuseppe Lanza and Raffale Ferri6. Iron uptake at the blood-brain barrier is influenced by sex and genotypeQuinn W. Wade, Brian Chiou and James R. Connor7. Caenorhabditis elegans and its applicability to studies on restless legs syndromePan Chen, Omamuyovwi Meashack Ijomone, Kun He Lee and Michael Aschner8. Role of MEIS1 in restless legs syndrome: From GWAS to functional studies in miceAaro V. Salminen, Daniel D. Lam and Juliane Winkelmann9. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndromeVivian Wanner, Celia Garcia Malo, Sofía Romero, Irene Cano-Pumarega and Diego García-Borreguero10. Idiopathic restless legs syndrome treatment: Progress and pitfalls?Imad Ghorayeb11. Treatment of pediatric restless legs syndromeLourdes DelRosso and Oliviero Bruni12. Pharmacological treatments of augmentation in restless legs syndrome patientsClaudia Trenkwalder and Walter Paulus